Sglt2 Inhibitor

ORLANDO — Nearly one-quarter of adults with difficult-to-control type 2 diabetes also have hypercortisolism, and treating hypercortisolism may also benefit glycemic control in those with both conditions, according to speakers.

ORLANDO — Semaglutide use was associated with significant reductions in worsening of kidney disease, cardiovascular events and all-cause death vs. placebo for adults with type 2 diabetes regardless of concomitant use of SGLT2 inhibitors.

ORLANDO — The U.S. health care community must focus on getting diabetes therapies, technology and tools into the hands of all people with diabetes, especially those with low incomes and living in rural communities, according to a speaker.

Presentations on the SURMOUNT-OSA, FLOW, INHALE-3 and TIGHT trials are among the many highlights at the American Diabetes Association’s 84th Scientific Sessions.

BOSTON — Lowering cardiovascular risk for people with type 2 diabetes requires effort from far beyond the clinician’s office, leveraging creative community partnerships that address social determinants of health, according to a speaker.

NEW ORLEANS — A consensus statement on managing diabetic ketoacidosis and hyperosmolar hyperglycemic state for adults with diabetes focuses on preventing recurrence and providing people with the tools to maintain glycemic control.

Adults who initiate a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those prescribed a DPP-IV inhibitor or an SGLT2 inhibitor, according to study findings published in The BMJ.

Annual expenditures for diabetes medications more than tripled in the U.S. from 2011 to 2020, and the increase played a role in an overall rise in money spent on prescription drugs, according to study findings.

Prices for most diabetes medications exceed their manufacturing costs, and the addition of generic or biosimilar medications could help to lower prices, according to study findings published in JAMA Network Open.

An experimental drug that inhibits aldosterone production reduced albuminuria in patients with chronic kidney disease, according to phase 2 study results published in The Lancet.